Medigene to Participate in Five Investment and Scientific Conferences in November

Planegg/Martinsried, (PresseBox) - Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in five international conferences:

BIO-Europe - Annual International Partnering Conference
Date: 3 - 5 November 2014
Location: Frankfurt am Main, Germany

The Society for Immunotherapy of Cancer (SITC)
Date: 7 - 9 November 2014
Location: National Harbor (Washington D.C.), USA
Poster Presentation on 8 November focusing the TCR immunotherapy platform titled "Generation of tumor antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo"

Jefferies Global Healthcare Conference
Date: 19 - 20 November 2014
Location: London, Great Britain

German Equity Forum
Date: 24 - 26 November 2014
Location: Frankfurt am Main, Germany
Company Presentation at 25 November 5 pm

BayImmuNet - International Symposium on Interventional Immunology from Cells to Drugs
Date: 13 - 14 November 2014
Location: Regensburg, Germany
Chair: Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

MediGene AG

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.